SOLICITATION NOTICE
B -- Oral bisphosphonates and risk of Esophageal cancer
- Notice Date
- 7/27/2011
- Notice Type
- Presolicitation
- NAICS
- 541990
— All Other Professional, Scientific, and Technical Services
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-110113-TG
- Archive Date
- 8/26/2011
- Point of Contact
- Terry Galloway, Phone: 301-402-4509, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
gallowaytl@mail.nih.gov, cr214i@nih.gov
(gallowaytl@mail.nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Boulevard, EPS Suite 600, Room 6074, Rockville, MD 20852, UNITED STATES. Description The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Nutritional Epidemiology Branch (NEB) plans to procure on a sole source basis the services of Kaiser Permanente, 2000 Broadway, Oakland, CA 94612 to provide extraction of relevant data from computerized databases and prepare analytic files suitable for epidemiologic research to assess whether use of oral bisphosphonates is associated with subsequent risk of esophageal cancer. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1). Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. The North American Industry Classification System code is 541990 and the business size standard is $7.0 Million. Period of Performance: Performance shall be for the period of twelve (12) months from date of award. Investigators in the NEB, Division of Cancer Epidemiology and Genetics, NCI conduct studies examining the etiology of esophageal and other cancers. Recently, a purported link between use of orally administered bisphosphonates (a class of drugs used to treat low bone density) and increased risk of esophageal cancer has garnered attention and is a new research focus. To date results are equivocal and more data examining this hypothesis is urgently needed. The NEB proposes to investigate the possible link between use of oral bisphosphonates and risk of esophageal cancer using the electronic databases available at Kaiser Permanente, an integrated managed care consortium. The proposed project requires a large general population of healthy subjects with regular medical care and who have electronically recorded data on prescription drug use. These subjects then had to be followed prospectively over a sufficient number of years to observe any new diagnosis of cancers of the esophagus. Because these cancers are rare, a very large study population is needed to have adequate power for detailed evaluation. The NEB also requires a comprehensive database of subject prescription drug use including formulation, prescribed dose, number of prescriptions, duration of use, and indication. In addition, it is important to evaluate and control for the potential confounding effect of a few well-established factors for these cancer. The contractor satisfies all of the above criteria. The Kaiser Permanente is uniquely qualified to carry out the tasks specified in the procurement because it meets all of the above specified criteria. Being the largest plan in the NCI-supported Cancer Research Network, a consortium of research Health Maintenance Organizations, the Northern California Kaiser Permanente has a current membership of over 3.2 million individuals. It is also the earliest established plan (since 1942) among the network of HMOs, ensuring both a large study population size and a sufficient length of follow-up to observe incident cancer diagnosis. Importantly, the plan has an electronic prescription drug database that extends back to 1995. More detailed data on potential confounding factors are available in these data. Kaiser Permanente is the only known source and one of the most widely used research databases for research on esophageal cancer of Managed Care plans. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI contracting office on or before 11:00 AM EST on August 11, 2011. No electronic capability statements will be accepted (i.e. email or fax), an original and one copy must be sent to the NCI contracting office to the address stated above. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Terry Galloway, Contract Specialist at gallowaytl@mail.nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference solicitation number NCI-110113-TG on all correspondences.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-110113-TG/listing.html)
- Record
- SN02512162-W 20110729/110727235004-7ff53b1aea878d536924825a018968eb (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |